02 September 2026

FDA approves first oral dermatomyositis drug

5 minute read

The once-daily targeted therapy offers a new treatment option for adults with the rare autoimmune disease.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...